Imatinib is an FDA-approved molecule since 2001 and is widely used for the treatment of various cancers, particularly in chronic myeloid leukemia characterized by the presence of the BCR-ABL fusion gene. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.